Holen Sie sich die Stockscreener-App
23.18
3.05%
-0.885
Schlusskurs vom Vortag:
$24.06
Offen:
$24.14
24-Stunden-Volumen:
182.82K
Relative Volume:
1.14
Marktkapitalisierung:
$1.24B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-32.20
EPS:
-0.7198
Netto-Cashflow:
-
1W Leistung:
-6.36%
1M Leistung:
-1.25%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$23.02
$25.52
1-Wochen-Bereich:
$23.02
$26.01
52-Wochen-Spanne:
$14.85
$28.38
Seaport Therapeutics Inc Stock (SPTX) Company Profile
Firmenname
Seaport Therapeutics Inc
Sektor
Branche
Telefon
617-807-4062
Adresse
6 TIDE STREET, BOSTON
Compare SPTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPTX
Seaport Therapeutics Inc
|
23.18 | 1.29B | 0 | 0 | 0 | -0.7198 |
VRTX
Vertex Pharmaceuticals Inc
|
520.68 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
802.99 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,005.68 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.22 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.66 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Seaport Therapeutics Inc Aktie (SPTX) Neueste Nachrichten
Seaport Therapeutics Says GlyphAllo Shows no Next-Morning Driving Impairment in Phase 1 Trial - marketscreener.com
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers - Business Wire
Citadel Advisors LLC Takes Position in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Braidwell LP Takes $10.86 Million Position in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Seaport Therapeutics, Inc. (NASDAQ:SPTX) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Alyeska Investment Group L.P. Makes New $1.63 Million Investment in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Seaport Therapeutics, Inc. Common Stock (NASDAQ: SPTX) Stock Price, News & Analysis - kalkine.ca
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference - BioSpace
Trv Gp Vi LLC Acquires New Shares in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Stock Price Down 5.2%Here's Why - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Now Covered by Analysts at JonesTrading - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Stock Price Up 6.4%Time to Buy? - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Sets New 52-Week HighHere's Why - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO - 24/7 Wall St.
Seaport Therapeutics' (SPTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Seaport Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Selvaraju Reiterates Buy on Seaport, Citing Differentiated Neuropsychiatry Pipeline and Unchanged $50 Price Target - TipRanks
Seaport Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | SPTX | US81221K1088 - marketscreener.com
Seaport Therapeutics (NASDAQ:SPTX) Reaches New 52-Week HighHere's What Happened - MarketBeat
Seaport Therapeutics Inc. (SPTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PureTech Health (SPTX holder) discloses 31.2% Seaport Therapeutics stake - Stock Titan
Stifel Maintains Seaport Therapeutics(SPTX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Top Seaport Therapeutics (SPTX) Competitors 2026 - MarketBeat
Seaport Therapeutics (SPTX) Stock Chart and Price History 2026 - MarketBeat
Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of Validation - Seeking Alpha
Seaport Therapeutics (SPTX) Institutional Ownership 2026 - MarketBeat
Seaport Therapeutics, Inc. (NASDAQ:SPTX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
HC Wainwright Has Negative Outlook for SPTX FY2026 Earnings - MarketBeat
Analysts’ Top NA Picks: Ceribell, Inc. (CBLL), Ethos Technologies Inc. Class A (LIFE) - The Globe and Mail
Seaport Therapeutics (SPTX): Daphne Zohar discloses 5.23M-share, 9.1% beneficial stake - Stock Titan
Seaport Therapeutics (SPTX) insider Steven M. Paul reports 6.3% stake - stocktitan.net
Seaport Therapeutics Reaffirmed at Buy as Clinical Pipeline Advances and $50 Price Target Remains Unchanged - TipRanks
Citi Maintains Seaport Therapeutics(SPTX.US) With Buy Rating, Maintains Target Price $35 - Moomoo
H.C. Wainwright Maintains Seaport Therapeutics(SPTX.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Seaport Therapeutics (NASDAQ:SPTX) Given Buy Rating at HC Wainwright - MarketBeat
Seaport Therapeutics, Inc. 2026 Q2 Financials: Forward-Looking Statements, Risks, and Company Highlights - Minichart
Seaport Therapeutics 2Q Research and Development Expenses Were $24.6M >SPTX - Moomoo
Seaport Therapeutics reports Q2 2026 net loss $62.6M, $427.3M cash; advances GlyphAllo and GlyphAgo - TradingView
Earnings Flash (SPTX) Seaport Therapeutics Posts Q2 Loss $1.78 a Share - marketscreener.com
Seaport Therapeutics, Inc. 2Q 2026: Revenue $0 Net loss $(62.6)M, EPS $(1.78) — 10-Q Summary - TradingView
Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - Yahoo Finance
Seaport Therapeutics, Inc. Revenue Breakdown – NASDAQ:SPTX - TradingView
Cambridge biotech raises $192M in upsized IPO ahead of major FDA decision - The Business Journals
SPTX Price Today: Seaport Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Seaport Therapeutics (SPTX) Earnings Date and Reports 2026 - MarketBeat
Michael Cunyuan Chen Net Worth (2026) - GuruFocus
Seaport Therapeutics, Inc. Revenue Breakdown – BOATS:SPTX - TradingView
Lana Gladstein Net Worth (2026) - GuruFocus
Enterprise value to EBITDA forward of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
Q2 Earnings Forecast for SPTX Issued By HC Wainwright - MarketBeat
Finanzdaten der Seaport Therapeutics Inc-Aktie (SPTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Seaport Therapeutics Inc-Aktie (SPTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ARCH Venture Partners XII, LLC | 10% Owner |
May 04 '26 |
Buy |
18.00 |
1,100,000 |
19,800,000 |
6,294,951 |
0.83%
2.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):